Currency In USD
| Previous Close | 0.7 |
| Open | 0.72 |
| Day High | 0.75 |
| Day Low | 0.69 |
| 52-Week High | 2.35 |
| 52-Week Low | 0.53 |
| Volume | 2.39M |
| Average Volume | 3.74M |
| Market Cap | 120.95M |
| PE | -1.65 |
| EPS | -0.44 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 1 |
| Change | 0.03 |
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Mar 09, 2026 12:30 PM GMT
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Po
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
GlobeNewswire Inc.
Mar 05, 2026 1:30 PM GMT
Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Fun
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
GlobeNewswire Inc.
Mar 02, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underly